A Phase 2 interventional study of SHJ002 and Vehicle in Corneal Erosion, sponsored by Sunhawk Vision Biotech, Inc.. Completed at 6 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Sunhawk Vision Biotech, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to measure efficacy and safety with 0.25% SHJ002 sterile ophthalmic solution compared to vehicle in treating corneal erosion in Sjogren's patients.
SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
Participants will be randomized to treatment with SHJ002 Ophthalmic Solution or vehicle which will be administered to each eye twice daily for 12 weeks.
Sunhawk Vision Biotech, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SHJ002 Ophthalmic Solution: topically administered to each eye twice daily for 12 weeks
Drug: SHJ002
Vehicle: topically administered to each eye twice daily for 12 weeks
Other: Vehicle
Topical ophthalmic
Topical ophthalmic
Change From Baseline to Week 12 in Total Corneal Fluorescein Staining
The total corneal fluorescein staining score will be assessed using the NEI grading scale (0-15 points; higher scores indicate more severe staining).
Time frame: Baseline to Week 12
Change From Baseline to Week 12 in Inferior Corneal Fluorescein Staining (iCFS)
iCFS score will be assessed using NEI regional grading (0-3 for the inferior region); higher scores represent more severe staining.
Time frame: Baseline to Week 12
Change From Baseline to Week 12 in SANDE Score
Symptom Assessment in Dry Eye (SANDE) questionnaire total score, on a 0-100 scale (higher = worse symptoms).
Time frame: Baseline to Week 12
| Milestone | SHJ002 | Vehicle |
|---|---|---|
| Started | 58 | 58 |
| Completed | 54 | 51 |
| Not completed | 4 | 7 |
The total corneal fluorescein staining score will be assessed using the NEI grading scale (0-15 points; higher scores indicate more severe staining).
| units on a scale | SHJ002 | Vehicle |
|---|---|---|
| Change From Baseline to Week 12 in Total Corneal Fluorescein Staining | -2.55 (-3.43 to -1.68) | -0.37 (-1.23 to 0.49) |
iCFS score will be assessed using NEI regional grading (0-3 for the inferior region); higher scores represent more severe staining.
| score on a scale | SHJ002 | Vehicle |
|---|---|---|
| Change From Baseline to Week 12 in Inferior Corneal Fluorescein Staining (iCFS) | -0.79 (-1.07 to -0.52) | -0.14 (-0.41 to 0.13) |
Symptom Assessment in Dry Eye (SANDE) questionnaire total score, on a 0-100 scale (higher = worse symptoms).
| score on a scale | SHJ002 | Vehicle |
|---|---|---|
| Change From Baseline to Week 12 in SANDE Score | -31.21 (-41.21 to -21.21) | -28.87 (-38.15 to -19.59) |
Collected over 84 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SHJ002 | 0/58 (0%) | 0/58 (0%) | 0/58 (0%) |
| Vehicle | 0/58 (0%) | 0/58 (0%) | 0/58 (0%) |
| Age, Continuous(years) | SHJ002 | Vehicle | Total |
|---|---|---|---|
| Mean | 60.95 ± 9.43 | 61.12 ± 10.96 | 61.03 ± 10.18 |
| Sex: Female, Male(Participants) | SHJ002 | Vehicle | Total |
|---|---|---|---|
| Female | 56 | 55 | 111 |
| Male | 2 | 3 | 5 |
| Race (NIH/OMB)(Participants) | SHJ002 | Vehicle | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 58 | 58 | 116 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2024 to primary completion in Apr 2025, 9 months.
Results were first posted in Aug 2025, 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sunhawk Vision Biotech, Inc.